News

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea

Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine a spotlight on moderate-to-severe obstructive sleep apnea (OSA), encouraging Americans to talk to their doctor Moderate-to-severe obstructive sleep apnea (OSA) is a serious, often underdiagnosed health condition that affects an estimated 24 million adults in the U.S.1 - many of whom are overweight or living with obesity2 - yet most cases remain undiagnosed Shaquille O'Neal joins Lilly's Don't Sleep...

News

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States

Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Lilly declares fourth-quarter 2025 dividend

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Lilly reports third-quarter 2025 financial results, highlights R&amp;D pipeline momentum and raises 2025 guidance

Lilly to Acquire Adverum Biotechnologies

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

News

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States

Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

Lilly confirms date and conference call for third-quarter 2025 financial results announcement

Lilly declares fourth-quarter 2025 dividend

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide

Lilly reports third-quarter 2025 financial results, highlights R&amp;D pipeline momentum and raises 2025 guidance

Lilly to Acquire Adverum Biotechnologies

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance